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Abstract
Background: In areas where Mycobacterium tuberculosis is endemic, tuberculosis is known to be the most common
cause of pericarditis. However, the difficulty in diagnosis may lead to late complications such as constrictive
pericarditis and increased mortality. Therefore, identification of patients at a high risk for poor prognosis, and
prompt initiation of treatment are important in the outcome of TB pericarditis. The aim of this study is to identify
the predictive factors for unfavorable outcomes of TB pericarditis in HIV-uninfected persons in an intermediate
tuberculosis burden country.
Methods: A retrospective review of 87 cases of TB pericarditis diagnosed at a tertiary referral hospital in South
Korea was performed. Clinical characteristics, treatment outcomes, complications during treatment, duration of
treatment, and medication history were reviewed. Unfavorable outcome was defined as constrictive pericarditis
identified on echocardiography performed 3 to 6 months after initial diagnosis of TB pericarditis, cardiac
tamponade requiring emergency pericardiocentesis, or death. Predictive factors for unfavorable outcomes were
identified.
Results: Of the 87 patients, 44 (50.6%) had unfavorable outcomes; cardiac tamponade (n = 36), constrictive pericarditis
(n = 18), and mortality (n = 4). 14 patients experienced both cardiac tamponade and constrictive pericarditis. During a
1 year out-patient clinic follow up, 4 patients required repeat pericardiocentesis and pericardiectomy was performed in
0 patients. In the multivariate analysis, patients with large amounts of pericardial effusion (P = .003), those with
hypoalbuminemia (P = .011), and those without cardiovascular disease (P = .011) were found to have a higher risk of
unfavorable outcomes.
Conclusion: HIV-uninfected patients with TB pericarditis are at a higher risk for unfavorable outcomes when presenting
with low serum albumin, with large pericardial effusions, and without cardiovascular disease.
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Background
Tuberculosis is a globally important infectious disease
with a high mortality and morbidity, with 1.5 million deaths
among the human immunodeficiency virus (HIV)–negative
and 0.52 million deaths among the HIV–positive popula-
tion, and with 9.4 million new cases reported each year
worldwide in 2014 [1]. In areas where Mycobacterium
tuberculosis is endemic, tuberculosis is known to be the
most common cause of pericarditis [2]. Although the inci-
dence of tuberculosis has decreased in many Western
countries, tuberculous (TB) pericarditis is still seen in many
patients in countries where tuberculosis is still an endemic
disease [3]. According to a study conducted in Tanzania,
TB pericarditis is also more likely to occur in HIV-infected
patients, whereas HIV-uninfected patients are likely to have
other etiologies of pericardial effusions [4].
Symptoms of TB pericarditis are generally nonspecific,
with an insidious onset [5]. The frequency of common
symptoms varies; however, cough, dyspnea, chest pain,
night sweat, orthopnea, and weight loss are generally the
most frequent symptoms [6, 7]. The diagnosis of TB
pericarditis can be made through the identification of the
tubercle bacillus from pericardial fluid; however, invasive
diagnostic pericardial biopsy is not an easy process to per-
form [8]. Anti-TB therapy is effective in reducing mortal-
ity among HIV-uninfected persons to 8–17% [9]. A
retrospective study conducted in Birmingham showed that
antituberculosis medication reduced the likelihood of de-
veloping constrictive pericarditis to 10–20% [7]. However,
the difficulty in diagnosis may lead to late complications
such as constrictive pericarditis and increased mortality
[5]. Therefore, identification of patients at a high risk for
poor prognosis, and prompt initiation of treatment are
important in the outcome of TB pericarditis.
We conducted this study to identify the predictive fac-
tors for the unfavorable outcomes of TB pericarditis in




We studied 166 patients with TB pericarditis diagnosed
at a tertiary referral hospital in South Korea during an
11-year period (January 2005 through December 2015).
Seventy-nine patients with diagnostic error (n = 11), miss-
ing laboratory data (n = 60), loss to treatment follow-up
(n = 7), or concomitant HIV infection (n = 1) were ex-
cluded. A total of 87 patients were reviewed. Patients who
were 18 years old or older who had been confirmed to
have probable or definite TB pericarditis were included.
Collected data
The following information were collected: demo-
graphic data, comorbidities, initial presenting symptoms,
laboratory results, echocardiographic findings, pericardial
biopsy results, pericardial fluid smear microscopy for acid
fast bacilli, pericardial culture for M. tuberculosis, anti-
microbial susceptibility of M. tuberculosis strains isolated
from the patients, pharmaceutical formulation use, steroid
use, and duration of treatment. Patient follow-up was
based on out-patient clinical visits.
Definitions
Definite TB pericarditis was defined as a diagnosis con-
firmed on a pericardial sample based on finding acid and
alcohol fast bacilli on microscopy, positive microbio-
logical culture for M. tuberculosis, presence of caseating
granulomata on histology, or positive nucleic acid test
(fluid or tissue) [10].
Probable TB pericarditis was defined as the presence
of a lymphocytic pericardial exudate with elevated ad-
enosine deaminase (ADA) activity ≥40 IU/L [10]. De-
tailed information on definitions of definite and
probable TB pericarditis is provided in Additional file 1:
Table S1.
Unfavorable outcome was defined as constrictive peri-
carditis identified on echocardiography performed 3 to
6 months after initial diagnosis of TB pericarditis, car-
diac tamponade requiring emergency pericardiocentesis,
or death [10].
Cardiovascular disease was defined in patients with a
history of hypertension, stable angina, and congestive
heart failure. The amount of pericardial effusion was
categorized into small (50–100 mL), moderate (100–
500 mL), or large (>500 mL) [11]. QuantiFERON-TB
Gold In-Tube assay was used for interferon-gamma
(IFN-γ) release assay (IGRA) diagnosis. The IFN-γ levels
(IU/mL) were measured, and the results were reported
as positive, negative, or indeterminate. Hypoalbumin-
emia was defined as serum albumin <3.0 g/dL. Body
mass index was calculated as the weight in kilograms di-
vided by the square of height in meters [12]. Red blood
cell (RBC) distribution width was defined as the index of
RBC size heterogeneity and RBC distribution width [13].
Statistical analysis
All factors were compared between the unfavorable and
favorable outcome groups. Categorical variables are pre-
sented as numbers and percentages. Continuous vari-
ables are expressed as mean ± standard deviation, unless
otherwise indicated. Categorical variables were com-
pared by using χ2 analysis, and continuous variables with
normal distributions were compared by using Student’s
t-test. We used the Mann–Whitney U-test to compare
the continuous variables with a skewed distribution.
Multivariate analysis was performed through logistic
regression to identify factors that independently and
significantly affected the outcome. All categories (large
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pericardial effusions, dyspnea, male sex, albumin, and
cardiovascular disease) were calculated as a percentage
with the 95% confidence interval (CI). All statistical tests
were performed by using IBM SPSS software for
Windows, version 20. P-values < 0.05 were considered
statistically significant.
Results
As shown in Table 1, of the 87 cases reviewed, 44
(50.6%) patients had unfavorable outcome. Of these pa-
tients, 36 patients received pericardial effusion drainage
due to cardiac tamponade, 18 patients had constrictive
pericarditis, and mortality in 4 patients. 14 patients ex-
perienced both cardiac tamponade and constrictive peri-
carditis. During a 1 year out-patient clinic follow-up, 4
patients required repeat pericardiocentesis, and pericar-
diectomy was performed in 0 patients. The causes of
mortality were acute heart failure due to stress-induced
cardiomyopathy, and cardiac tamponade.
There was a male predominance in patients with un-
favorable outcome compared with those with favorable
outcome (56.8% vs. 34.9%, P = .040). Other baseline
characteristics of underlying diseases such as solid organ
cancer, hematologic malignancies, hypothyroidism, old
pulmonary tuberculosis, chronic renal disease, chronic
liver disease, chronic lung disease, autoimmune disease,
and diabetes mellitus did not show any difference be-
tween outcomes. On the other hand, patients without a
history of cardiovascular disease were found to have a
higher risk of unfavorable outcomes (34.1% vs. 55.8%,
P = .042).
Table 1 shows the laboratory results of the study par-
ticipants at the time of admission. Patients presenting
with a low albumin level at the time of admission tended
to have unfavorable outcomes (3.3 ± 0.7 vs. 3.6 ± 0.6,
P = .047). Hypoalbuminemia defined as serum albumin
lower than 3.0 g/dL had higher risk of unfavourable
outcome (38.6% vs. 16.3%, P = .020). Pericardial ADA
levels did not show a statistical significance between
the two groups (85 vs. 63, P = .986).
Table 1 describes the clinical symptoms and findings
of the study participants. Dyspnea was the most com-
mon presenting symptom, and the presence of dyspnea
showed a correlation to a higher risk of unfavorable out-
comes (84.1% vs. 62.8%, P = .024). Patients who pre-
sented with large amounts of pericardial effusion,
exceeding 500 mL on the echocardiogram, showed a
higher risk for unfavorable outcomes (79.5% vs. 53.5%,
P = .010). Concomitant pulmonary tuberculosis was seen
in 6 (14%) patients with favorable outcomes and 4
(9.1%) patients with unfavorable outcomes, with no sig-
nificant difference (P = .521). The mean duration of
symptom onset was 7 days in the favorable group and
14 days in the unfavorable group, showing that patients






Age (years) 66.5 ± 18.2 67.1 ± 15.5 .873a
Male, n (%) 15 (34.9) 25 (56.8) .040b
BMI 22.8 ± 4.9 22.9 ± 3.2 .871a
Underlying diseases, yes (%)
Solid cancer 2 (4.7) 4 (9.1) .676b
Hematologic malignancy 0 (0.0) 3 (6.8) .241b
Hypothyroidism 0 (0.0) 2 (4.5) .504b
Cardiovascular disease 24 (55.8) 15 (34.1) .042b
Old tuberculosis 6 (14.0) 8 (18.2) .592b
Chronic renal disease 4 (9.3) 1 (2.3) .202b
Chronic liver disease 0 (0.0) 3 (6.8) .241b
Chronic lung disease 3 (7.0) 5 (11.4) .713b
Autoimmune disease 1 (2.3) 4 (9.1) .360b
DM 7 (16.3) 12 (27.3) .300b
Laboratory findings
Leukocyte count (PE) 2456 (1020–3500) 1110 (225–3420) .205c
ADA 63 (48–103) 85 (46–125) .228c
Albumin, g/dL 3.6 ± 0.6 3.3 ± 0.7 .047a
Hypoalbuminemia, n (%)e 7 (16.3) 17 (38.6) .020b
Symptoms
Dyspnea 27 (62.8) 37 (84.1) .024b
Chest pain 17 (39.5) 16 (36.4) .761b
Fever 14 (32.6) 8 (18.2) .123b
Palpitation 2 (4.7) 7 (15.9) .157b
Duration, days 7 (5–21) 14 (7–28) .433c
PE amount .023d
Small 8 (18.6) 4 (9.1) .198b
Moderate 12 (27.9) 5 (11.4) .062b
Large 23 (53.5) 35 (79.5) .010b
Concomitant pulmonary
tuberculosis
6 (14.0) 4 (9.1) .521b
Origin
Lung 8 (18.6) 6 (13.6) .528b
Reactivation and inapparent 35 (81.4) 38 (86.4)
Hospital stay, days 12.2 ± 11.0 14.3 ± 10.5 .348a
Antituberculosis medication
Duration, months 6.4 ± 2.3 6.6 ± 3.3 .776a
Steroid
Users, yes (%) 19 (44.2) 22 (50.0) .587b
Duration, weeks 12.1 ± 7.4 11.6 ± 7.3 .808a
Data are expressed as the mean ± standard deviation or number (percentage)




cMann–Whitney U-test, median (interquartile range)
dLinear-by-linear association
edefined as serum albumin concentration below 3.0 g/dL
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with unfavorable outcomes were admitted for hospital
care earlier; however, the difference was not statistically
significant.
All strains of M. tuberculosis isolated from the patients
were antimicrobial susceptible strains in this study.
Anti-TB medication (standard isoniazid, rifampin, eth-
ambutol, and pyrazinamide for 2 months followed by
maintenance 4 months of isoniazid, rifampin, and eth-
ambutol) was taken for a duration of 6.4 ± 2.3 months in
the favorable outcome group and 6.6 ± 3.3 months in the
unfavorable outcome group, with no significant differ-
ence (P = .776). Steroids were administered in 19 (44.2%)
patients with favorable outcomes and in 22 (50%) pa-
tients with unfavorable outcomes (P = .587). The mean
duration of steroid use (prednisolone 60 mg/day for
four weeks, followed by 30 mg/day for four weeks,
15 mg/day for two weeks, and 5 mg/day for 1 week
[14]) was 12.1 ± 7.4 weeks in the favorable outcome
group and 11.6 ± 7.3 weeks in the unfavorable out-
come group (P = .808). In the Kaplan Meier analysis,
patients with cardiac tamponade had a lower rate of
survival compared to patients with favorable outcomes
(mean survival days: 1 day vs. 28 days, P < .001).
In the multivariate analysis, a large amount of pericar-
dial effusion on echocardiogram (odds ratio [OR] 5.974,
95% CI 1.811–19.703, P = .003), hypoalbuminemia (OR
4.905, 95% CI 1.443–16.667, P = .011), and absence of
underlying cardiovascular disease (OR 0.255, 95% CI
0.089–0.733, P = .011) were shown to be independent
predictive factors for unfavorable outcomes (Table 2).
Discussion
The infection of M. tuberculosis in the pericardium usu-
ally occurs through the retrograde lymphatic spread of
the infection from the lungs, mediastinum structures,
and adjacent lymph nodes, or through the hematogenous
spread from the spine or from genitourinary infection
[15]. The pathogenesis of TB pericarditis is a delayed
hypersensitivity response induced by the activation of lym-
phocytes releasing lymphocytokines that activate macro-
phages, leading to granuloma formation and pericardial
effusion [16]. The histopathological pattern is mostly af-
fected by the immune state, and HIV-infected persons
with severely depleted CD4 lymphocytes present with less
granuloma on biopsy [17].
While there is no difference in the sex–age pattern of
the disease in industrialized countries, the disease rate in
adult men exceeds those in women in developing coun-
tries [18]. The prevalence of M. tuberculosis infection in
developing countries is similar to these findings, with a
male predominance in patients older than 15 years [18].
The difference in the tuberculosis prevalence and sex is
explained by the fact that women in developing coun-
tries have a passive attitude about visiting health-care fa-
cilities owing to cultural reasons [19]. The result of our
study shows that male sex confers a higher risk for un-
favorable outcomes.
The normal amount of pericardial fluid is 10–15 mL
between the pericardial layers, and acts as a lubricant
[20]. An inflammatory process of any cause results in
an increased production of pericardial fluid [20, 21].
In previous studies, patients with hemodynamic com-
promise have large amounts of pericardial effusion on
echocardiogram and are often associated with a
higher mortality rate [2, 22]. Hemodynamically signifi-
cant pericardial effusions leading to cardiac tampon-
ade are commonly apparent with dyspnea [6, 23].
Dyspnea on exertion is a key symptom of acute peri-
cardial tamponade that requires emergency peri-
cardiocentesis and has a high risk for mortality [24].
Choi et al. reported that patients who were initially
more symptomatic, and had echogenic pericardial ef-
fusions tended to require pericardiectomy more often,
and had more advanced disease [25]. From these re-
sults, it can be presumed that patients with large
amounts of pericardial effusion are likely to experi-
ence dyspnea leading to hemodynamic compromise,
which is correlated with unfavorable outcomes.
In this study, the presence of cardiovascular disease
was a predictive factor for favorable outcomes. In this
study, patients with an underlying cardiovascular dis-
ease were regularly being followed by the hospital,
which may have resulted in the earlier detection of
symptoms or provided the availability of earlier med-
ical care, compared with patients who did not con-
duct regular hospital visits. For these reasons, patients
with an underlying cardiovascular disease have a low
risk for unfavorable outcomes. However, further stud-
ies for general applicability, and to confirm the valid-
ity of this assertion is needed.
In a study conducted by Reuter et al., patients unin-
fected with HIV had significantly higher serum protein
and globulin levels than HIV-infected tuberculosis pa-
tients [8]. Although there was no statistical significance
in serum albumin levels, the serum albumin/globulin
Table 2 Multivariate analysis of predictive factors for unfavorable
outcomes in patients with tuberculous pericarditis
Variables OR (95% CI) P-value
Large PE 5.974 (1.811–19.703) .003
Cardiovascular disease 0.255 (0.089–0.733) .011
Hypoalbuminemiaa 4.905 (1.443–16.667) .011
Dyspnea 2.792 (0.852–9.145) .090
Male 2.063 (0.745–5.713) .163
OR odds ratio, CI confidence interval, PE pericardial effusion
adefined as serum albumin concentration below 3.0 g/dL
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ratios showed significantly lower results in the HIV-
uninfected TB pericarditis group [8]. One study in India
identified serum albumin concentrations <3.2 g/dL as a
risk factor for increased mortality in HIV-infected pa-
tients with tuberculosis [26]. However, there have been
no studies on serum albumin level and its prognostic
value in HIV-uninfected patients with TB pericarditis.
The significance of this study is that it shows serum al-
bumin as an independent variable predictive of unfavor-
able outcome in HIV-uninfected patients.
ADA is considered a marker for cellular immunity and
is associated with the differentiation of lymphocytes
[27]. A cutoff value of 40 U/L in the pericardial fluid is
considered to have a specificity and sensitivity of 72%
and 89% in diagnosis of TB pericarditis, respectively
[28]. A median ADA of 97 U/L in the pericardial fluid
was seen in the patients of this study.
The South Korean population receives routine Bacille
Calmette-Guérin (BCG) vaccination after birth, and
again at age 12 or 13 years if the child proves to be a tu-
berculin skin test (TST) nonresponder. Because BCG
vaccination shows cross-reactivity with the result of the
TST, we considered serum IGRA to be more appropriate
than the TST for the diagnosis of latent tuberculosis
[29]. In a study by Burgess et al., the measurement of
pericardial fluid IGRA with a cutoff level of >200 pg/L
was highly specific (100%) [30]. Future studies in larger
sample numbers may confirm the use of pericardial effu-
sion IGRA measurement as a promising method for the
rapid diagnosis of TB pericarditis.
Anti-TB therapy reduces the incidence of mortality
and constrictive pericarditis [7, 31]. The treatment dur-
ation and regimen approach in HIV-uninfected patients
is the same as those for pulmonary tuberculosis [32, 33].
The 6-month treatment regimen has similar effective-
ness to that of longer treatment duration, and is gener-
ally recommended in susceptible tuberculosis cases [33].
Although the antimycobacterial treatment duration was
slightly longer in the unfavorable group, it did not have
any statistical difference with a median treatment dur-
ation of 6 months (6.6 ± 3.3 vs. 6.4 ± 2.3, P = .776).
In several prior studies, the use of corticosteroids sig-
nificantly reduced the incidence of constrictive pericardi-
tis, and thereby patients at high risk of progression to
constrictive pericarditis are suggested to receive an ad-
junctive use of corticosteroids with a recommended
starting dose of 60 mg/day tapered during 11 weeks
[10, 14, 34]. Another 10 years follow-up study by
Strang et al. described that prednisolone reduced the
risk of death due to pericarditis, and the need for re-
peat pericardiocentesis in patients with constrictive
pericarditis or pericardial effusion [35, 36]. In our
study, among the 40 patients with effusion or con-
strictive pericarditis, 21 were treated with steroids
during a mean duration of 11 weeks but did not show any
association to unfavorable outcomes. Hence, there was a
difference in outcomes compared to previous clinical tri-
als. However, these previous trials had relatively small
samples, and a recent randomized trial of 1400 patients
(431 whom were HIV-negative) by Mayosi et al. dem-
onstrated similar results to our study, that routine
use of adjuvant corticosteroids did not have any sig-
nificant effect on the primary outcomes of death and
cardiac tamponade [10].
This study has several limitations. First, this study was
conducted retrospectively. Therefore, information on
nutritional status, which could influence the treatment
outcome, was not available. Second, only a small number
of patients were included. Third, while it is plausible that
routine follow up for cardiovascular disease may have
enhanced earlier detection of symptoms, the explanation
for this association may have limitations for general ap-
plicability. Finally, this study was performed in a country
with an intermediate tuberculosis prevalence. Future
multicenter prospective studies in countries with a di-
verse tuberculosis epidemiology are needed to confirm
the predictive factors for unfavorable outcomes in HIV-
uninfected persons.
Conclusion
HIV-uninfected patients with TB pericarditis are at a
higher risk for unfavorable outcomes when presenting
with hypoalbuminemia, with large pericardial effusion,
and without cardiovascular disease. This study may
prompt clinicians to perform early diagnosis and treat-
ment in patients with these risk factors, which may lead
to a decrease in mortality and late complications such as
constrictive pericarditis.
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